Principles of Surgical Oncology

1.Biological Basis of Surgical Oncology

Surgical oncology is grounded in an understanding of tumour biology that extends far beyond anatomy. The decision to operate — and how to operate — is shaped by the biological behaviour of the tumour: its growth kinetics, invasive capacity, metastatic potential, and response to systemic agents. Modern surgical oncology has moved decisively away from the principle of 'maximum tolerable surgery' toward 'minimum effective surgery', guided by molecular profiling, multimodal treatment, and high-quality surgical technique.

Carcinogenesis follows a multi-step process in which normal cells acquire successive mutations conferring growth advantage. The Hanahan and Weinberg hallmarks of cancer framework identifies ten acquired capabilities: sustained proliferative signalling, evasion of growth suppressors, resistance to cell death, replicative immortality, induction of angiogenesis, activation of invasion and metastasis, avoidance of immune destruction, tumour-promoting inflammation, deregulated cellular energetics, and genome instability. Each hallmark represents a potential therapeutic target and shapes tumour behaviour the surgeon must anticipate.

Local tumour invasion proceeds through disruption of basement membrane integrity, degradation of extracellular matrix (ECM) by matrix metalloproteinases (MMPs), epithelial-mesenchymal transition (EMT), and directed cell migration. EMT — in which epithelial cells acquire mesenchymal phenotype (loss of E-cadherin, gain of vimentin and N-cadherin) — is central to both local invasion and the first steps of haematogenous metastasis. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) are clinical manifestations of this process now entering routine oncological practice.

The metastatic cascade requires: local invasion, intravasation into blood or lymph vessels, survival in circulation, extravasation at a distant site, micrometastasis formation, and finally outgrowth to clinically detectable macrometastasis. Each step is inefficient — fewer than 0.01% of circulating tumour cells form successful metastases. The concept of the 'pre-metastatic niche' (Kaplan, Nature 2005) — bone marrow-derived progenitor cells conditioning distant organs before tumour cell arrival — has reshaped understanding of early systemic spread.

Tumour microenvironment (TME) profoundly influences surgical outcomes. High stromal content (desmoplasia) creates physical barriers to drug delivery and is associated with worse prognosis in pancreatic and breast cancer. Tumour-infiltrating lymphocytes (TILs), particularly CD8+ cytotoxic T-cells, correlate with improved survival in colorectal, breast, and melanoma and are increasingly used as prognostic biomarkers. Immunotherapy-responsive tumours — characterised by microsatellite instability-high (MSI-H) or high tumour mutational burden (TMB-H) — may achieve pathological complete response with neoadjuvant checkpoint inhibition, potentially allowing organ-preserving strategies.

2.Surgical Margins: R-Classification and Oncological Adequacy

The completeness of surgical resection is the single most surgically controllable prognostic factor in solid tumour surgery. The International Union Against Cancer (UICC) R-classification provides the universal language for describing resection completeness: R0 (no residual tumour — microscopically clear margins), R1 (microscopic residual tumour at the resection margin), and R2 (macroscopic residual tumour). This classification applies to the primary resection and any metastasectomy and must be recorded for every oncological procedure.

The minimum acceptable margin width beyond which R0 can be declared remains tumour-specific and controversially debated. For colorectal liver metastases, the historical 1cm margin has been superseded by evidence that margin width is less important than the presence or absence of tumour cells at the margin — a sub-millimetre clearance achieved with anatomical precision yields equivalent outcomes to wider margins. For retroperitoneal sarcoma, 1mm clearance is frequently unavoidable given anatomical constraints, yet is functionally R0 if no tumour cells are at the inked margin. For pancreatic cancer, the Royal College of Pathologists UK protocol defines R1 as tumour within 1mm of the resection margin — an international consensus yet to be universally adopted.

The concept of circumferential resection margin (CRM) is particularly important in rectal cancer. MRI-defined CRM threat — tumour within 1mm of the mesorectal fascia propria on preoperative staging — is the key indication for neoadjuvant chemoradiotherapy. Pathological CRM involvement (R1) increases local recurrence risk from 6% to 22% (MERCURY Study Group, Lancet 2006) and is an independent predictor of worse disease-specific survival. Reporting CRM distance in mm should be mandatory in all rectal cancer pathology reports.

3.Principles of Lymphadenectomy

Regional lymph node dissection serves two purposes in surgical oncology: therapeutic (removal of nodal metastases) and staging (accurate pathological N-category). These purposes are not always separable and the balance between them drives the extent of lymphadenectomy in each tumour type. The therapeutic value of nodal dissection — whether removal of microscopic nodal disease improves survival beyond what systemic therapy achieves — remains one of the most debated questions in surgical oncology.

Minimum lymph node yield is mandated for adequate staging in most tumour types. For colorectal cancer, NCCN requires ≥12 lymph nodes for adequate staging — fewer nodes suggest inadequate resection or sampling and may lead to understaging. For gastric cancer, the Japanese Gastric Cancer Association (JGCA) mandates ≥16 nodes. For breast cancer, sentinel node biopsy has replaced routine axillary dissection for clinically node-negative disease, with ACOSOG Z0011 establishing that completion axillary dissection can be safely omitted in patients with 1–2 positive sentinel nodes undergoing breast-conserving surgery with whole-breast irradiation.

The sentinel lymph node (SLN) concept, pioneered by Morton for melanoma (1992) and Giuliano for breast cancer (1993), relies on the principle that lymphatic drainage from a primary tumour follows an anatomically predictable route to the first-echelon (sentinel) node before involving further nodes. Negative SLN accurately predicts negative nodal basin with 95% accuracy, sparing the majority of patients the morbidity of complete nodal dissection. Technical requirements include dual-agent mapping (radioisotope + blue dye or fluorescent tracer), minimum retrieval of ≥3 sentinel nodes, and experienced surgeon performance.

Skip metastases — involvement of non-sentinel, higher-echelon nodes without SLN positivity — occur in a minority of cases (5–10% in gastric cancer, <3% in colorectal cancer) and represent a biological phenomenon rather than a technical failure. Their existence does not invalidate SLN biopsy but does highlight the importance of understanding tumour-specific lymphatic patterns before adopting sentinel node techniques outside their validated contexts.

4.Neoadjuvant and Adjuvant Therapy: Rationale and Sequencing

The integration of systemic therapy with surgical resection defines modern multimodal oncology. The timing of therapy relative to surgery — neoadjuvant (before) versus adjuvant (after) — is not arbitrary but reflects evidence-based rationale for each tumour type. The fundamental advantage of neoadjuvant therapy is the opportunity to treat micrometastatic disease in a patient with intact performance status, to downsize the primary tumour (potentially converting borderline-resectable to resectable disease), to assess tumour chemoresponsiveness in vivo, and to reduce the risk of intraoperative tumour cell dissemination.

The concept of total neoadjuvant therapy (TNT) — delivering all planned chemotherapy and radiotherapy before surgery — has emerged most powerfully in rectal cancer (RAPIDO trial, 2021; PRODIGE-23, 2021). TNT improves pathological complete response (pCR) rates from approximately 15% to 25–28%, potentially enabling non-operative management (watch-and-wait) in complete clinical responders. Achieving pCR after TNT correlates with excellent oncological outcomes — 5-year disease-free survival exceeding 90% in complete responders in the OPRA trial.

Adjuvant chemotherapy after curative resection aims to eliminate residual micrometastatic disease not removed by surgery. Its benefit must be established by randomised evidence demonstrating survival improvement — not assumed. Level-1 evidence supports adjuvant FOLFOX for stage III and high-risk stage II colorectal cancer (MOSAIC trial, André, NEJM 2004), adjuvant S-1 or capecitabine for D2-resected gastric cancer (ACTS-GC; CLASSIC trial), and adjuvant endocrine therapy for hormone receptor-positive breast cancer (decades of EBCTCG meta-analyses).

5.Multidisciplinary Tumour Board

The multidisciplinary tumour board (MDT) — also termed tumour board, multidisciplinary team meeting, or case conference — is the institutional mechanism by which complex oncological decisions are made collectively by specialists with complementary expertise. Far from a bureaucratic formality, MDT review has been demonstrated in multiple studies to change treatment recommendations in 20–32% of cases reviewed, with changes predominantly toward more active and guideline-concordant management.

A complete MDT for surgical oncology includes, at minimum: the operating surgeon, medical oncologist, radiation oncologist, diagnostic radiologist (with subspecialty expertise), pathologist, and specialist nurse or patient navigator. For complex tumours — rectal cancer, hepatopancreatic-biliary, peritoneal oncology — additional subspecialists (hepatologist, interventional radiologist, palliative care physician) and allied health professionals are incorporated. A general and digestive surgery department holds weekly oncological MDT meetings with mandatory presentation of all new solid tumour diagnoses before treatment initiation.

Effective MDT function requires more than attendance — it requires high-quality imaging review, complete pathological reporting, documented treatment recommendations, and follow-up on outcomes. MDT dysfunction is associated with time pressure, incomplete imaging, absent key specialists, and failure to document decisions. Regular MDT audit using validated tools (TEAM tool, MDT-MOT) is recommended by NICE and ESMO to maintain quality standards.

6.Minimally Invasive Oncological Surgery

The adoption of minimally invasive surgery (MIS) in oncology — laparoscopic and robotic approaches — has been one of the most consequential technical developments of the past three decades. Initial scepticism about oncological equivalence has been systematically addressed by multiple high-quality randomised controlled trials demonstrating non-inferiority for cancer-specific outcomes in selected tumour types and settings. The established benefits of MIS — reduced blood loss, shorter hospital stay, faster recovery, and reduced wound complications — are now achievable without oncological compromise.

Robotic surgery offers potential advantages over standard laparoscopy in anatomically challenging settings — the narrow male pelvis for TME, precise dissection near critical nerves in thyroid and parathyroid surgery, and reconstruction after HPB resection. The ROLARR trial (Jayne, JAMA 2017) failed to demonstrate superiority of robotic over laparoscopic TME for conversion rate (primary endpoint) or oncological outcomes. Robot-assisted surgery currently offers ergonomic advantages to the surgeon without proven patient-level oncological benefit over laparoscopic equivalents.

7.Tumour Microenvironment & Immunotherapy

The tumour microenvironment (TME) is the complex ecosystem surrounding cancer cells, comprising immune cells, stromal cells, endothelial cells, and non-cellular components including the extracellular matrix and soluble mediators. Far from being a passive bystander, the TME actively promotes or suppresses tumour growth, invasion, metastasis, and therapeutic response. Modern oncology increasingly recognises that treating cancer means targeting not just the tumour cell, but its entire supporting ecosystem.

The immune component of the TME is the central target of immunotherapy. CD8+ cytotoxic T-lymphocytes (CTLs) are the primary anti-tumour immune effectors: they recognise cancer-specific antigens presented on MHC class I molecules and execute tumour cell killing. However, tumours deploy multiple immune evasion mechanisms: downregulation of MHC-I expression, upregulation of inhibitory immune checkpoints (PD-L1/PD-1 axis; CTLA-4), secretion of immunosuppressive cytokines (TGF-β, IL-10), and recruitment of regulatory T-cells (Tregs) and tumour-associated macrophages (TAMs) of the M2 immunosuppressive phenotype.

Tumour-infiltrating lymphocytes (TILs) are increasingly recognised as prognostic and predictive biomarkers. In triple-negative breast cancer, each 10% increase in stromal TILs is associated with an 18% reduction in the risk of recurrence or death. The International Immuno-Oncology Biomarker Working Group has standardised TIL assessment methodology. For pathological specimens from surgical resections, TIL quantification is rapidly becoming a routine component of the pathology report in breast and other tumour types.

Perioperative immune status influences oncological outcomes beyond immunotherapy response. Surgical stress induces transient immunosuppression through neuroendocrine activation, releasing cortisol and catecholamines that suppress NK cell activity and promote regulatory T-cell expansion. This perioperative immune window — the period of maximum immunosuppression immediately post-surgery — may facilitate metastatic outgrowth. Minimising surgical stress, optimising anaesthetic technique (avoiding opioids where possible), and early return to nutrition are all strategies to limit perioperative immunosuppression.

8.Liquid Biopsy & Molecular Diagnostics

Liquid biopsy refers to the analysis of tumour-derived material in blood or other body fluids — principally circulating tumour DNA (ctDNA), circulating tumour cells (CTCs), and tumour-derived extracellular vesicles (exosomes). These technologies enable minimally invasive molecular profiling of tumour biology, with direct implications for surgical decision-making, treatment selection, and surveillance. The clinical utility of liquid biopsy is advancing rapidly, with several assays achieving regulatory approval and guideline incorporation.

Circulating tumour DNA (ctDNA) is released from tumour cells through apoptosis, necrosis, and active secretion. It constitutes a fraction of the total cell-free DNA (cfDNA) in plasma, ranging from <0.1% (early-stage tumours) to >50% (high-burden metastatic disease). ctDNA analysis can detect tumour-specific mutations (e.g., RAS, BRAF, PIK3CA), copy number alterations, and methylation patterns. Key clinical applications include: genotyping when tissue biopsy is insufficient or inaccessible; monitoring treatment response; detecting molecular residual disease (MRD) after curative surgery; and identifying resistance mechanisms at progression.

Circulating tumour cells (CTCs) represent intact cancer cells shed into the peripheral blood. The CellSearch system (FDA-cleared) counts epithelial CTCs in 7.5mL blood — ≥5 CTCs is associated with worse prognosis in metastatic breast, colorectal, and prostate cancer. CTCs enable downstream phenotypic and genomic analysis, including HER2 status, EMT markers, and resistance mutations. CTC enumeration is available as a prognostic tool in clinical practice, though its role in changing treatment decisions remains primarily investigational.

Tumour mutational burden (TMB) — measured as the number of somatic mutations per megabase of tumour genome — predicts response to PD-1/PD-L1 checkpoint inhibition in a tumour-agnostic manner. TMB-high (≥10 mut/Mb) tumours respond to pembrolizumab regardless of histology, following FDA tumour-agnostic approval based on the KEYNOTE-158 basket trial. The relationship between TMB and MSI-H is strong but imperfect — approximately 15% of TMB-high tumours are MSS and vice versa. Both biomarkers should be assessed in tumours being considered for immunotherapy.

9.Perioperative Risk Assessment

Perioperative risk assessment in oncological surgery is a structured process to determine whether a patient can safely tolerate the planned operation, and to optimise modifiable risk factors before surgery. The fundamental distinction in operability assessment is between tumour resectability (technical surgical feasibility) and patient operability (physiological capacity to tolerate surgery). Both must be evaluated independently — a technically resectable tumour in a physiologically unfit patient does not justify surgery.

Cardiopulmonary exercise testing (CPET) provides objective, quantitative assessment of integrated cardiorespiratory reserve — the capacity to deliver oxygen to exercising muscles. The anaerobic threshold (AT) — the VO2 at which anaerobic metabolism supplements aerobic ATP production — is the most clinically useful CPET parameter for surgical risk stratification. AT <11 mL/kg/min is associated with a 3-fold increase in major post-operative complications after major abdominal and thoracic surgery. CPET is the reference standard for risk assessment before major oncological procedures in patients with uncertain cardiorespiratory reserve.

Frailty — a syndrome of diminished physiological reserve across multiple organ systems — is distinct from comorbidity and is the strongest independent predictor of adverse outcome after major surgery in older patients. The Clinical Frailty Scale (CFS, 1–9), modified Frailty Index (mFI), and FRAIL questionnaire are validated frailty screening tools. CFS ≥5 (moderately frail) is associated with 3-fold higher 30-day mortality and 2-fold higher major complication rates after major abdominal surgery. All patients over 65 undergoing major oncological surgery should undergo frailty screening.

Nutritional assessment and optimisation are integral components of perioperative risk management. Malnutrition — defined by ESPEN as BMI <18.5 kg/m² with unintentional weight loss >5% in 3 months, or reduced food intake combined with reduced muscle mass — affects 20–50% of surgical oncology patients. It doubles post-operative infection rates, quadruples anastomotic leak risk, and triples 30-day mortality. Preoperative nutritional optimisation (enteral or parenteral nutrition for 7–10 days) should be offered to severely malnourished patients before elective cancer surgery.

10.Surgical Margins — Principles & Definitions

Margin assessment in surgical oncology begins with the surgeon and ends with the pathologist — but both must share a common language and protocol to ensure meaningful data. The surgeon must orient the specimen, mark the critical margins (radial, deep, circumferential), and communicate to the pathologist which margins are anatomically constrained and which were deliberately extended. The pathologist must apply standardised inking, slicing, and measurement protocols. Without this surgeon-pathologist dialogue, margin data is unreliable and cannot guide subsequent decisions.

The concept of the 'threatened margin' versus the 'involved margin' is critical in preoperative planning. On preoperative imaging (MRI, CT), a threatened margin is defined as tumour within 1mm of a critical fascial boundary — the mesorectal fascia in rectal cancer, the muscularis propria in bladder tumours, the renal capsule in adrenal tumours. A threatened margin identifies patients who require neoadjuvant therapy to achieve R0 status or who need a wider resection that was not initially planned. A margin that is threatened on preoperative imaging may still be pathologically clear after resection — the surgeon must dissect at or beyond the threatened boundary.

Intraoperative assessment of margins by surgeons (gross inspection and palpation) has poor correlation with microscopic margin status. In breast-conserving surgery, intraoperative gross assessment identifies only 30–40% of positive margins that are subsequently detected on permanent histology. Intraoperative techniques that improve margin detection include specimen radiology (immediate post-excision X-ray in breast surgery), frozen section of the targeted margin, and fluorescence guidance with tumour-avid contrast agents. None of these technologies has replaced definitive permanent histology as the gold standard for margin assessment.